Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Efficacité et sécurité du tofacitinib chez les patients atteints de spondylarthrite ankylosante en fonction de la prise antérieure d'antirhumatismaux modificateurs de la maladie : Une analyse post hoc

ACR Open Rheumatol. 2023;5(12)632–643 doi 10.1002/acr2.11601

Deodhar A,

Marzo-Ortega H,

Wu J,

Wang C,

Dina O,

Kanik KS,

Fallon L,

Gensler LS

In this post hoc analysis by Deoodhar, et al., the authors found that tofacitinib demonstrated greater efficacy than placebo in bDMARD-naïve and TNFi-IR AS patients. They also found that safety event rates for tofacitinib therapy were numerically higher in the TNFi-IR subgroup than the bDMARD-naïve subgroup.

Keywords:

July 2023

La douleur et l'inflammation en tant que médiateurs de l'effet du traitement au tofacitinib sur la fatigue des patients atteints de spondylarthrite ankylosante : Une analyse de médiation

Rheumatol Ther 2023;10(4):1073–1087 doi 10.1007/s40744-023-00570-0

Dina O,

Kristensen, et al. used mediation modelling to show that tofacitinib indirectly improved fatigue symptoms via back pain and morning stiffness. This study was carried out using FACIT-F- and BASDAI Q1-based models to determine the relationship between these variables.